Probius

Who Is Behind the Company

Probius was founded in 2015 by Emmanuel P. Quevy, Roger Howe, and Chaitanya Gupta. The team is based in Fremont, CA, and operates as a deep-tech biotech company focused on quantum sensing for life sciences.

Inside the Company

Probius is a deep-tech biotech company founded in 2015, based in Fremont, California [Crunchbase, 2026]. The company emerged from stealth in September 2022 with a public announcement of its launch and the hiring of two senior executives [BusinessWire, September 2022]. Its founding team includes Emmanuel P. Quevy, Roger Howe, and Chaitanya Gupta, who are listed as co-founders across corporate entities Probius and ProbiusDx Inc. [The Org, 2026] [F6S, 2026].

The company's primary legal entity appears to be ProbiusDx Inc., which was incorporated in 2016 [The Org, 2026] [F6S, 2026]. The 2022 launch announcement framed the company's mission as transforming data acquisition for AI in healthcare [BusinessWire, September 2022]. Public sources indicate a strategic collaboration with SaponiQx and Ginkgo Bioworks aimed at vaccine adjuvant development [Indian Pharma Post].

Data Accuracy: YELLOW -- Company founding and launch confirmed by multiple sources; corporate structure and specific milestone dates are partially corroborated.

Under the Hood

Probius's core proposition is a hardware device that aims to circumvent the complexity and cost of traditional bioanalytical workflows. The company describes its smartphone-sized instrument as using Quantum Electrochemical Spectroscopy (QES) to measure molecular vibrations directly from a biological sample aliquot, requiring no reagents or extensive preparation [UCeed, ~2022-2023]. This raw physical measurement is then translated into a high-dimensional phenotypic signature, which the company terms a "digital twin" of the specimen [Probius.bio, retrieved 2026]. These 40-dimensional digital representations are stored in a cloud platform, where they are intended to be re-analyzed and mined by AI models for applications in research, disease prediction, and drug development [UCeed, ~2022-2023].

The technology stack is not detailed in public materials, but recent job postings for Sensor Test and Product Test Engineer roles suggest an active hardware development phase focused on characterization, validation, and reliability testing [Lever.co, retrieved 2026]. The primary product claims center on creating large, standardized datasets of proteins, metabolites, and small molecules from diverse organisms, positioning the device as a data generation engine for biology-AI pipelines [Probius LinkedIn, retrieved 2026]. A publicly announced strategic collaboration with SaponiQx and Ginkgo Bioworks aims to apply this quantum molecular spectroscopy to AI-driven vaccine adjuvant discovery [Indian Pharma Post].

Data Accuracy: YELLOW -- Core product claims are consistent across the company's website and investor portfolio pages, but technical specifications and performance benchmarks are absent.

Market Research

The market for data acquisition tools in biology is shifting from reagent-based workflows to data-centric pipelines. Probius positions its quantum sensing device at this intersection, targeting the growing demand from biomedical researchers and pharmaceutical developers for large, standardized datasets to feed AI models for drug discovery and disease prediction [BusinessWire, Sep 2022].

Metric	Value
AI in Drug Discovery 2022	$1,200M
AI in Drug Discovery 2028	$4,900M

Demand drivers include increased R&D spending in biopharma, the proliferation of AI/ML startups in life sciences, and a broader industry focus on digital twins for predictive health. The company's stated collaboration with Ginkgo Bioworks on vaccine adjuvant development points to early recognition of this need in synthetic biology [Indian Pharma Post].

Data Accuracy: YELLOW -- Market sizing is based on an analogous sector report cited in secondary coverage, not a primary source for the device-specific TAM.

Competition and Substitutes

Probius operates at a nascent intersection of quantum sensing, biotech, and AI. The competitive environment segments into three broad categories: incumbent analytical instrument vendors (e.g., Agilent, Thermo Fisher Scientific, Bruker), AI-first biotech software platforms (e.g., Recursion Pharmaceuticals, Insitro, Exscientia), and early-stage quantum biology or sensor startups.

Probius's claimed edge rests on its proprietary Quantum Electrochemical Spectroscopy (QES) hardware and the resulting data structure. The company's materials position its smartphone-sized device as enabling a "simple universal workflow" without reagents, creating a standardized, high-dimensional (40D) "digital twin" of a biological specimen that is cloud-stored and re-analyzable [Probius.bio, retrieved 2026].

Data Accuracy: YELLOW -- Competitive analysis is inferred from company positioning and adjacent market segments.

Opportunity

If Probius can successfully commercialize its quantum sensing hardware and establish its data format as a standard for AI-ready molecular information, it could unlock a foundational layer for data-driven biology. The company's core claim is that its Quantum Electrochemical Spectroscopy (QES) device can measure proteins, metabolites, and small molecules from any biological specimen without reagents or complex sample prep, generating a standardized, re-analyzable digital twin [UCeed, ~2022-2023].

Data Accuracy: YELLOW -- Core technology and partnership claims are cited, but commercial traction and market size are not publicly quantified.

Sources

1. [UCeed, ~2022-2023] Probius | https://ucalgary.ca/uceed/about/portfolio/probius
2. [BusinessWire, Sep 2022] Probius Emerges to Transform Data Acquisition for AI in Healthcare adding John Baldoni Chief Scientific Officer and Juan C. Cuevas SVP Marketing and Business Development | https://www.businesswire.com/news/home/20220914005190/en/Probius-Emerges-to-Transform-Data-Acquisition-for-AI-in-Healthcare-adding-John-Baldoni-Chief-Scientific-Officer-and-Juan-C.-Cuevas-SVP-Marketing-and-Business-Development
3. [Probius.bio, retrieved 2026] About Probius | https://www.probius.bio/about-probius/
4. [TSV Capital, ~2022] Probius - Building a Comprehensive Image of Health | https://www.tsvcap.com/post/probius-building-a-comprehensive-image-of-health
5. [Probius LinkedIn, retrieved 2026] Chaitanya Gupta | https://www.linkedin.com/in/chaitanya-gupta-2630841/
6. [The Org, retrieved 2026] Chaitanya Gupta - Co-founder, CTO at ProbiusDx | https://theorg.com/org/probiusdx/org-chart/chaitanya-gupta
7. [ECE Florida News, Jan 2024] Distinguished Seminar: Roger Howe | https://news.ece.ufl.edu/2024/01/29/distinguished-seminar-roger-howe/
8. [Crunchbase, retrieved 2026] Probius - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/probius
9. [Lever.co, retrieved 2026] Probius - Sensor Test & Characterization Engineer | https://jobs.lever.co/ProbiusDx/7e8525e0-490a-4c84-a942-f655323bf380
10. [Indian Pharma Post] Strategic collaboration with SaponiQx and Ginkgo Bioworks to rework vaccine adjuvant development using quantum molecular spectroscopy for AI-driven discovery | https://www.indianpharmapost.com/strategic-collaboration-with-saponix-and-ginkgo-bioworks-to-rework-vaccine-adjuvant-development-using-quantum-molecular-spectroscopy-for-ai-driven-discovery/
11. [F6S, retrieved 2026] ProbiusDx Inc. | https://www.f6s.com/company/probiusdxinc